Truffle funded Deinove with Miroslav Radman, Professor at the Faculty of Medicine of René Descartes, who is committed to a radical innovation approach that aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the nutrition and cosmetics industries.
See website
Synoptical view
- Truffle investment
- € 9M
- Stock
- Deinove is listed on EURONEXT GROWTH since april 2010
Management team
Board of Directors
In summary
Deinove has developed a unique and exhaustive expertise in the field of rare bacteria that it knows how to decipher, cultivate, optimize to reveal their unsuspected possibilities and thus make them produce on an industrial scale biosourced molecules with activities of interest. To this end, since its creation, Deinove has built up and documented an unrivalled reserve of biological diversity that it exploits thanks to a technological platform that is unique in Europe. The company is developing in two areas of activity:
- ANTIBIOTICS, new generation anti-infectives: Phase II clinical trial of a first candidate antibiotic. The Company is also pursuing systematic exploration of biodiversity to supply its portfolio with new leads, notably through partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance).
- BIOACTIVES, active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: Deinove already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). She also runs an animal nutrition program with the April Group.
In video
They talk about it
It is urgent to innovate to discover the antibiotics of tomorrow. All over the world, the effectiveness of antibiotics is decreasing; infections that we thought had disappeared forever are resurfacing, thanks to pathogenic bacteria that no longer fear existing therapies.
KEY STEPS
2010
Entry into the EURONEXT market
2015
Deinove obtains its American patent for ethanol without oil
2017
The Agir project led by the Deinove group receives €14.6 million from a programme operated by BPIfrance to develop new antibiotics
2019
Deinove and Dow sign a collaboration agreement for the development of a new cosmetic active ingredient
New
"Deinove has developed a unique and exhaustive expertise in the field of rare bacteria that it knows how to decipher, cultivate, optimize to reveal their unsuspected possibilities and thus make them produce on an industrial scale biosourced molecules with activities of interest. To this end, since its creation, Deinove has built up and documented an unrivalled reserve of biological diversity that it exploits thanks to a technological platform that is unique in Europe. The company is developing in two areas of activity:
- ANTIBIOTICS, new generation anti-infectives: Phase II clinical trial of a first candidate antibiotic. The Company is also pursuing systematic exploration of biodiversity to supply its portfolio with new leads, notably through partnerships with Naicons and bioMérieux (AGIR program supported by Bpifrance).
- BIOACTIVES, active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: Deinove already markets a first innovative active ingredient, a second in partnership with Greentech, while two others are in development with Oléos (Hallstar Group). She also runs an animal nutrition program with the April Group."
